Moving Science Forward in Alzheimer’s Disease Clinical Trials

Register free: http://www.appliedclinicaltrialsonline.com/act_w/alzheimers

Event overview:
Alzheimer’s disease affects more than 20 million people worldwide. More people will be impacted as the cohort of adults aged 65 and older rises and if disease modifying therapies are not fully approved. Clinical trials for Alzheimer’s disease are scientifically and operationally challenging. Sponsors need innovative solutions to drive new therapies to market.

In this webinar, IQVIA experts will share how to harness data, technology, and advanced analytics to inclusively recruit the right patients in the right places at the right time into Alzheimer’s disease clinical trials.

3 Key take-aways

1. Operationalize the trial designs optimized to bring Alzheimer’s disease therapies forward

2. Generate appropriately representative patient enrollment into your Alzheimer’s disease clinical trials

3. Investigate the impact of heterogeneity in your patient population

Speakers

Tiffany Chow, MD, MS
Sr. Medical Strategy Lead, CNS Center of Excellence
IQVIA

Dr. Tiffany Chow is an experienced industry physician with 25 years of clinical research in both academic neuroscience and research on elucidating the neurobiology of Alzheimer’s and other dementias, applying radioligand PET imaging and functional neuroimaging methods, neuropsychiatric assessments and genomic testing in order to develop clinically meaningful therapies. She has contributed to thought leadership in frontotemporal dementias (FTD) and Alzheimer’s disease clinical trial design. Dr. Chow served as Medical Director, Director of Clinical Monitoring, Diversity Strategist for the Alzheimer’s Therapeutic Research Institute at the University of Southern California prior to joining IQVIA. She earned her MS at Stanford University and completed her MD training at Rush Medical College.

Carolina Rubel, PhD
Sr. Director Portfolio Head Neurodegenerative Disease, CNS Project Leadership
IQVIA

Carolina Rubel has over 20 years experience in the clinical research industry within the CRO sector, working the last 10 years in the area of neurodegenerative diseases overseeing complex and multi-regional programs in Alzheimer, Parkinson and ALS. She is currently the Portfolio Head of Neurodegenerative Diseases (NDD) in CNS project leadership, accountable for executive oversight and operational delivery within the NDD group and is involved in strategy development and providing operational expertise. Her responsibilities span the full clinical development duration, from program planning and start-up to close-out and reporting.

Russell Reeve, PhD
VP Biostatistics and Decision Sciences
IQVIA

Dr. Russell Reeve is the global head of Biostatistics and Decision Sciences within IQVIA Research & Development Services. This organization has more than 300 professionals providing biostatistical and pharmacological services, including trial design, analysis, and reporting. Biostatistics has offices in all major markets, with offices in North America, Europe, Africa, and Asia.

Dr. Reeve has been in the pharmaceutical industry since 1992, and has been at IQVIA since 2007, with increasing levels of responsibility.

Dr. Reeve earned a BS in Mathematics and Statistics from Utah State University, an MS in Operations Research from Rensselaer Polytechnic Institute, and a PhD in Statistics from Virginia Polytechnic Institute and State University. Dr. Reeve has published numerous peer-reviewed papers and book chapters, is a reviewer for major statistical journals, has been on the Advisory Board of George Mason University Statistics Department, and on the Board of Directors of North Carolina State University’s Colleges of Sciences Foundation.

Register free: http://www.appliedclinicaltrialsonline.com/act_w/alzheimers